- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03999294
Bmgim Music Therapy Method in Reducing Stress in Patients With Inflammatory Bowel Disease
The Influence of the Bmgim Music Therapy Method in the Reduction of Stress in Patients With Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis): Quantitative and Qualitative Study
Inflammatory bowel disease (IBD) is a term that defines a chronic disease characterized by inflammation of the intestine. It includes ulcerative colitis (UC) and Crohn's disease (CD). The objective of the study was to administer a treatment based on a group adaptation of the BMGIM in patients with inflammatory bowel disease (IBD) and assess its impact on state of mind, quality of life, anxiety, depression, immunocompetence as a marker of well-being, and levels of acute and chronic stress.
To achieve the objectives a quasi-experimental, quantitative, qualitative, analytical, and prospective study was performed. 41 patients with IBD divided into a test group (24 patients), who received 8 sessions over 8 weeks, and a control group (17 patients). A saliva sample was taken from each patient before and after each session to determine cortisol levels (acute stress) and IgA (immunocompetence) using ELISA. A series of questionnaires were completed as follows: HADS (perceived anxiety), MOOD (state of mind), and CCVEII (quality of life). Similarly, a hair sample was taken before the first and after the last session to determine the cumulative cortisol level (chronic stress) using ELISA.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Valencia, Spain, 46010
- Universitat de Valencia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Over 18 years old,
- Diagnosed IBD (EC or UC) in the remission phase,
- They did not receive treatment with corticosteroids at least in the two months prior to the start of the study,
- They did not receive any extra pharmacological treatment,
- Attend the collaborating hospital center with the study, in this case, the University General Hospital of Valencia,
- Attend the schedule and schedule established for the study,
- Accept the conditions of participation in the study indicated in the signed informed consent prior to the start of the study
- * Do not take corticosteroids during the 8 weeks between the pre-test and the post-test,
- * Perform the pre-test before starting session 1 (in case of experimental group) or appointment 1 (in case of control group); and then the retest at the end of session 8 (in the case of an experimental group) or appointment with nursing after 8 weeks (in the case of a control group).
- * In the case of the patients belonging to the experimental group, who at the end of the 8 weeks of treatment would have attended at least 6 of the 8 sessions established (and that, obligatorily, 2 of them were 1 and 8, where the shots were taken) sample and completed the questionnaires).
Exclusion Criteria:
The patients who were excluded from this study were those who did not meet the requirements indicated in the inclusion criteria, or who showed aversion or rejection to this type of therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental Group
|
The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
|
|
No Intervention: Control Group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in biological markers in saliva samples using enzyme-linked immunosorbent biological markers assay (ELISA) (PRE and POST Measures).
Time Frame: Baseline up to 8 weeks of treatment
|
Quantifying change in biological markers in saliva samples using enzyme-linked immunosorbent assay (ELISA).
(IgA level & Salivary Cortisol) comparing pre and post intervention
|
Baseline up to 8 weeks of treatment
|
|
Change in biological markers in hair using enzyme-linked immunosorbent assay (ELISA).(PRE and POST Measures).
Time Frame: Baseline up to 8 weeks of treatment
|
Quantifying change in biological markers in hair (Cortisol Hair) comparing pre and post intervention
|
Baseline up to 8 weeks of treatment
|
|
Change in Hospital Anxiety and Depression Scale (HADS) (PRE and POST Measures)
Time Frame: Baseline up to 8 weeks of treatment
|
14 items.
7 items for Anxiety and 7 for Depression.
The score for the items is evaluated on a Likert scale ranging from 0 to 3 points, where 0 represents never or almost never, 1 a little or from time to time, 2 somewhat less than before or not as intense, and 3 maximum or almost always.
Lastly, it is worth mentioning that these scales are interpreted based on the sum of each dimension, with 21 as the maximum, both for depression and for anxiety.
Higher values represent a worse outcome.
Observing change comparing pre and post intervention
|
Baseline up to 8 weeks of treatment
|
|
Change in Short-form Questionnaire on Quality of Life in IBD (CCVEII-9) (PRE and POST Measures)
Time Frame: Baseline up to 8 weeks of treatment
|
9 items grouped in a single dimension The final score is expressed on a scale of 0 to 100 points, such that a lower score corresponds to a lower quality of life and vice versa.
Observing change comparing pre and post intervention
|
Baseline up to 8 weeks of treatment
|
|
Change in the MOOD questionnaire (PRE and POST Measures).
Time Frame: Baseline up to 8 weeks of treatment
|
The scale evaluates the frequency of the different states of mind (happiness, anger, sadness, and fear) based on 20 items (4 dimensions of 5 items each).
The responses for the items were measured using a 3-point Likert scale (1=never, 2=sometimes, 3=often).
Each dimension range from 1 to 3.
There is not a total of all dimensions together.
a lower score corresponds to high level fo that mood (lower values= a betwer outcome on anger, sadness, and fear and worst outcome on hapiness).
Observing change comparing pre and post intervention
|
Baseline up to 8 weeks of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Vicente Javier Prado Gascó, Universitat de Valencia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- musicoterapia25f2015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
Turku University HospitalUniversity of TurkuRecruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn Disease in Remission | Crohn Disease of Small IntestineFinland
-
Tzaneio General HospitalRecruitingCrohn Disease (CD) | Crohn Disease of Ileum | Kono S Anastomosis | Extended Mesenteric ExcisionGreece
-
L2 Bio, LLCFDAMap; Akan Biosciences, Inc.Not yet recruitingCrohn&Amp;#39;s | Crohn&Amp;#39;s Disease (CD)
-
University Hospital, Clermont-FerrandNot yet recruiting
-
Central Hospital, Nancy, FranceNot yet recruitingCrohn Disease (CD)France
-
GLSMED Learning Health S.A.Not yet recruiting
-
University Hospital, Clermont-FerrandActive, not recruiting
-
University Hospital, GrenobleNot yet recruiting
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...RecruitingCrohn Disease (CD)France
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
Clinical Trials on BMGIM Music Therapy Method
-
Association de Musicothérapie Applications et Recherches...Centre d'Evaluation et du Traitement de la Douleur CHU Saint-Eloi; Unité de... and other collaboratorsCompleted
-
Policlinico Universitario, CataniaRecruitingNewborn Morbidity | Premature Infant DiseaseItaly
-
University of ThessalyCompletedQuality of Life | Rheumatoid Arthritis | Chronic PainGreece
-
Aalborg UniversityAretaieion University Hospital; SONORA Organisation for Music Therapy and ResearchUnknownCancer, Breast | Cancer, Metastatic | Cancer Ovaries | Cancer Uterus CervixGreece
-
Case Comprehensive Cancer CenterCompletedMultiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin LymphomaUnited States
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedAutonomic Nervous System Imbalance | Hypothalamic Pituitary Adrenal Axis SuppressionUnited States
-
University of PennsylvaniaConestoga High SchoolCompletedStress | Cognitive Impairment | DementiaUnited States
-
Wayne State UniversityCompletedNeurological DisordersUnited States
-
Icahn School of Medicine at Mount SinaiCompletedSARS-CoV 2 | Dyspnea | Post Covid-19 RespiratoryUnited States
-
Icahn School of Medicine at Mount SinaiCompleted